Search results
Results From The WOW.Com Content Network
According to some projections, it will be worth $44 billion by 2030 -- up from $2.5 billion in 2022. Though many companies are looking to challenge Eli Lilly and Novo Nordisk in this field, don't ...
Goldman Sachs recently predicted that data center power demand will grow 160% by 2030, which will lead to 3.3 billion cubic feet per day of new natural gas demand. Utilities will need to invest in ...
On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark ...
The Alcon product line has expanded from pharmaceuticals to the surgical arena. Today, Alcon has operations in 75 countries and its products are sold in over 180 countries. Nestlé conducted an initial public offering of 25% of its stake in Alcon in 2002. The stock is traded under the ticker symbol ALC.
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic ...
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily therapies for lowering intraocular pressure with mechanisms to treat patients ...
The 2020s will feature increasingly dramatic pharmaceutical and nutritional discoveries, largely driven by advanced AI—not enough to cure aging on their own, but sufficient to extend many lives ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.